IX BIOPHARMA LTD.

(Company Registration No. 200405621W) (Incorporated in the Republic of Singapore)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 48.814.711 NEW ORDINARY SHARES IN THE CAPITAL OF IX BIOPHARMA LTD.

- DESPATCH OF NOTIFICATION AND APPLICATION FORMS

Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Company's announcements dated 8 June 2021, 21 June 2021, 22 June 2021, and 30 June 2021 in relation to the Rights Issue (the "Earlier Announcements"). Any reference to the time of day herein shall be a reference to Singapore time.

The board of directors (the "Board" or "Directors") of iX Biopharma Ltd. (the "Company") refers to the Earlier Announcements in relation to the proposed renounceable non-underwritten rights issue of up to 48,814,711 new ordinary shares in the capital of the Company (the "Rights Shares"), at an issue price of S\$0.20 for each Rights Share, on the basis of seven (7) Rights Shares for every 100 existing ordinary shares in the issued and paid up capital of the Company (the "Rights Issue").

The Board wishes to announce that the Notification, together with the Application Forms (collectively, the "**Documents**"), have been despatched to the Entitled Shareholders today. To access the Offer Information Statement, Entitled Shareholders may refer to the instructions set out in the Notification.

Entitled Shareholders who do not receive the Documents may obtain copies of the same from CDP or the Share Registrar, during the period from the date the Rights Issue commences up to the Closing Date (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company), as the case may be, during normal business hours in the following manner:

- (a) in the case of Entitled Depositors, by making a request through CDP's customer services via email to asksgx@sgx.com or via telephone at +65 6535 7511; or
- (b) in the case of Entitled Scripholders, from the address of the Share Registrar, Tricor Barbinder Share Registration Services, at 80 Robinson Road, #02-00, Singapore 068898.

For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the Rights Issue is only made in Singapore and the Notification, the Offer Information Statement and its accompanying documents will not be despatched (or disseminated in accordance with such laws or regulations as may be applicable) to Foreign Shareholders or into any jurisdiction outside Singapore. Accordingly, Foreign Shareholders will not be entitled to participate in the Rights Issue.

BY ORDER OF THE BOARD

Lee Wei Hsiung / Wang Shin Lin, Adeline Company Secretaries

5 July 2021

IMPORTANT NOTICE

This announcement is for information only and does not constitute or form part of any offer or invitation to sell or issue or subscribe for, or any solicitation of any offer to acquire, any Rights Shares or to take up any entitlements to Rights Shares in any jurisdiction in which such an offer or solicitation is unlawful. No person should acquire any Rights Shares except on the basis of the information contained in an offer information statement to be lodged by the Company with the Singapore Exchange Securities Trading Limited, acting as agent on behalf of the Monetary Authority of Singapore. The information contained in this announcement is not for release, publication or distribution to persons in the United States and should not be distributed, forwarded to or transmitted in or into any jurisdiction where to do so might constitute a violation of applicable securities laws or regulations. The issue, exercise or sale of Rights Shares and the acquisition or purchase of the Rights Shares are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions.

The distribution of this announcement into jurisdictions other than Singapore may be restricted by law. Persons into whose possession this announcement and such other documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.